ReviewDrugs2009
Endometriosis: current therapies and new pharmacological developments.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Patient characteristics and lifestyle determinants of quality of life among women with endometriosis: a systematic review.Reproduction & fertility · 2026Pooled it
- Impact of dienogest pretreatment on IVF-ET outcomes in patients with endometriosis: a systematic review and meta-analysis.Journal of ovarian research · 2023Pooled it
- Gonadotropin-releasing hormone analogues for endometriosis.The Cochrane database of systematic reviews · 2023Pooled it
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.The Cochrane database of systematic reviews · 2010Pooled it
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment.Archives of gynecology and obstetrics · 2012Trial
- Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials.Health and quality of life outcomes · 2010Trial
- Surgical Management of Urinary-Symptom-Dominant Endometriosis: Addressing Persistent Voiding Dysfunction and Pelvic Floor Factors.International urogynecology journal · 2026Review
- Building Disease Models for Endometriosis: iPSCs as Game-Changers.International journal of molecular sciences · 2026Review
- A biopsychosocial perspective on endometriosis: the importance of psychological inflexibility.Archives of gynecology and obstetrics · 2026Article
- Hormonal Treatment of Endometriosis: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The effect of endometriosis on oocyte quality: mechanisms, diagnosis and treatment.Archives of gynecology and obstetrics · 2025Review
- Circulating micronutrients levels and their association with the risk of endometriosis.Frontiers in nutrition · 2024Article
- A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022.Acta medica Philippina · 2024Article
- A framework for assessing interactions for risk stratification models: the example of ovarian cancer.Journal of the National Cancer Institute · 2023Article
- Endometriosis and Opioid Receptors: Are Opioids a Possible/Promising Treatment for Endometriosis?International journal of molecular sciences · 2023Review
- Analysis of Adverse Events and Medical Errors in Long-Term Hormone Treatments for Endometriosis: A Study Based on the US Food and Drug Administration Event Reporting System.International journal of women's health · 2022Article
- Predictive Factors of Conception and the Cumulative Pregnancy Rate in Subfertile Couples Undergoing Timed Intercourse With Ultrasound.Frontiers in endocrinology · 2021Article
- Article
- Article
- Effect of miR-194-5p regulating STAT1/mTOR signaling pathway on the biological characteristics of ectopic endometrial cells from mice.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic inflammatory condition that is responsive to management with steroids. The establishment of a steady hormonal environment and inhibition of ovulation can temporarily suppress ectopic implants and reduce inflammation as well as associated pain symptoms. In terms of pharmacological management, the currently available agents are not curative, and treatment often needs to be continued for years or until pregnancy is desired. Similar efficacy has been observed from the various therapies that have been investigated for endometriosis. Accordingly, combined oral contraceptives and progestins, based on their favourable safety profile, tolerability and cost, should be considered as first-line options, as an alternative to surgery and for post-operative adjuvant use. In situations where progestins and oral contraceptives prove ineffective, are poorly tolerated or are contraindicated, gonadotrophin-releasing hormone analogues, danazol or gestrinone may be used. Future therapeutic options for managing endometriosis must compare favourably against existing agents before they can be considered for inclusion into current practice. Finally, as reproductive prognosis is not ameliorated by medical treatment, it is not indicated for women seeking conception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.